Single Agent PEMAZYRE® - for Cholangiocarcinoma
Single Agent PEMAZYRE® (Pemigatinib) for unresectable locally advanced or metastatic Cholangiocarcinoma with a Fibroblast Growth Factor Receptor 2 (FGFR2) fusion or other rearrangement.
PEMAZYRE® is given orally once daily with or without food. Monitor patients closely for vomiting, diarrhea, hyper or hypophosphatemia. Treatment continued until disease progression or unacceptable toxicity.
Drug Mode Given Standard Dose Days to Be Given Frequency Solution Volume Duration
PEMAZYRE® (Pemigatinib) PO QD 13.5 mg D1 thru D14 q21 N/A N/A N/A